ArticlePLOS global public health2025
Admission screening for extended-spectrum cephalosporin-resistant and carbapenem-resistant Enterobacterales colonization at a referral hospital in Botswana: A one-year period-prevalence survey, 2022-2023.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) and carbapenem-resistant Enterobacterales (CRE) are significant contributors to infection-related mortality in low- and middle-income countries. Colonization with ESCrE and/or CRE can precede infection and serve as a reservoir for transmission within healthcare facilities and the community.We conducted a 12-month period-prevalence study, screening patients for ESCrE and CRE upon admission to a referral tertiary hospital Emergency Department in Botswana. Rectal swabs were collected within 24 hours of hospital arrival. Colonization was identified using selective culture media and confirmed using automated susceptibility testing. Associations between ESCrE/CRE colonization, and clinical and demographic variables were analysed using univariate and multivariable logistic regression. Among 802 patients, 24.1% (n = 193) were colonized with ESCrE, and 1.5% (n = 12) with CRE. ESCrE colonization was associated with recent hospitalization (within the last six months) (aOR 1.76, 95% CI 1.11-2.79), borehole water use (aOR 3.95, 95% CI 1.12-13.87), indwelling medical devices (aOR 2.19, 95% CI 1.08-4.48), and age < 1 year (aOR 2.09, 95% CI 1.32-3.30). CRE colonization was associated with antiretroviral drug use (cOR 6.60, 95% CI 1.72-25.36). Infants (<1 year) had over three times the odds of ESCr/CR-Klebsiella spp. colonization compared to adults (cOR 3.60, 95% CI 1.82-7.13). Infant age, recent healthcare exposure, indwelling medical devices, and borehole water use were key risk factors for ESCrE colonization, highlighting the need for targeted infection prevention strategies in Botswana. The identified potential association between CRE colonization and antiretroviral drug use warrants further investigation to elucidate any possible links and drivers between HIV care and antimicrobial resistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.